Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471858 | 0.90 | KDM4E (0.60) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL3942245 | 0.83 | KDM4E (0.53) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL20409590 | 0.83 | KDM4E (0.53) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL10441956 | 0.82 | ATM (0.48) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL3762622 | 0.81 | KDM4E (0.51) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL10837608 | 0.81 | KDM4E (0.56) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL2088974 | 0.81 | KDM4E (0.51) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL20410949 | 0.81 | KDM4E (0.56) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL4447566 | 0.81 | KDM4E (0.51) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL20411007 | 0.81 | HRH3 (0.54) | LMNAHTTMAPTKDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101528690-A | Isoindoline derivatives for the treatment of arrhythmias | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-6133286-A | ANTAGONISTS; ANTIINFLAMMATORY AGENTS FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHER SKIN DISORDERS, E.G., ECZEMA, ERYTHEMA, PRURITUS AND ACNE; STROKE, REPERFUSION INJURY, GRAFTING | PFIZER INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6117874-A | AROMATIC RING-SUBSTITUTED 4-HYDROXYTETRAHYDROQUINOLINES | PFIZER INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6051601-A | USEFUL OF INFLAMMATORY DISORDERS INCLUDING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHER SKIN DISORDERS SUCH AS ECZEMA, ERYTHEMA, PRURITUS AND ACNE, STROKE AND OTHER FORMS OF REPERFUSLON | PFIZER INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0963755-A2 | Use of benzopyranes for preventing allograft rejection | Pfizer Products Inc. (US) | 1999-12-15 | — | — | EP | disclosed |
| EP-0943339-A2 | Method of preventing allograft rejection | Pfizer Products Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5684046-A | LEUKOTRIENE B4 ANTAGONIST AS ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | PFIZER INC (US) | 1997-11-04 | — | — | US | disclosed |
| CN-1160399-A | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists | PFIZER (US) | 1997-09-24 | — | — | CN | disclosed |
| EP-0785935-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| EP-0785930-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B 4? (LTB 4?) ANTAGONISTS | PFIZER INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| EP-0623123-B1 | Benzopyran and related LTB4-antagonists | PFIZER (US) | 1997-04-23 | — | — | EP | disclosed |
| US-5552435-A | ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS | PFIZER INC. (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996011925-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996011920-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4 (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0623123-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993015067-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | LMNA 228/4885HTT 3361/4885MAPT 4504/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | LMNA 461/4885HTT 3086/4885MAPT 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.